Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom

View original at nasdaq.com
“TSMC anticipates its operating profit margin to be 57.5% in Q2 (at the midpoint of its guidance range).”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia anticipates $1 trillion in AI data center chip sales in 2026 and 2027

    60% confidence
  • TSMC anticipates operating profit margin of 57.5% in Q2 2026 at the midpoint of guidance range

    60% confidence
  • TSMC could be the ultimate pick-and-shovel AI stock for 2026 and beyond due to its wider reach in AI chips than Nvidia and Broadcom

    60% confidence
  • TSMC expects revenue to increase by more than 30% in 2026, revised from earlier forecast of close to 30%

    60% confidence
  • Stock Advisor's total average return is 994%, outperforming the S&P 500's 199%

    60% confidence
  • TSMC is expected to continue raising prices for its advanced chip nodes over the next four years

    60% confidence
  • Broadcom sees $100 billion in AI chip revenue in fiscal 2027, up from $20 billion in fiscal 2025

    60% confidence
  • TSMC forecasts 32% year-over-year revenue increase in Q2 2026 to $39.6 billion

    60% confidence

Data points we hold from this source

Taiwan Semiconductor Manufacturing Company · forward earnings multiple25 ratio
Taiwan Semiconductor Manufacturing Company · net profit margin50.5 percent
Taiwan Semiconductor Manufacturing Company · eps3.49 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom — Source | Via News | Via News